NCT01272791已完成2 期
A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
Peregrine Pharmaceuticals19 个研究点 分布在 2 个国家目标入组 70 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 19
- 主要终点
- Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
研究概览
简要总结
The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
详细描述
This is prospective, randomized, open-label, multicenter, phase 2 study of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent has been obtained.
- •Adults of 18 years of age or older with a life expectancy of at least 3 months.
- •Patients with histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Adequate hematologic function (ANC ≥ 1,500 cells/µL; hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL).
- •Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min).
- •Adequate hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN); ALT and AST may be <5 x ULN if due to liver metastases.
- •PT/INR ≤ 1.5 × ULN.
- •aPTT ≤ 1.5 × ULN.
- •Female patients must have a negative urine or serum pregnancy test at screening (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal).
- •All patients of reproductive potential must agree to use an approved form of contraception (as determined by the investigator).
排除标准
- •Neuroendocrine tumors (carcinoid, islet cell cancer) of the pancreas.
- •NYHA Class III or IV, cardiac function, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease.
- •Known brain, leptomeningeal or epidural metastases.
- •Radiation therapy within 7 days of Study Day 1, lack of recovery from previous therapeutic radiation, or planned radiation therapy during the study period.
- •Previously received any systemic treatment for pancreatic cancer, including prior neoadjuvant or adjuvant chemotherapy for lower stage disease.
- •Previously malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years.
- •Severe chronic obstructive or other pulmonary disease with hypoxemia.
- •Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery.
- •Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
- •Ongoing therapy with oral or parenteral anticoagulants; patients on low-dose anticoagulants to maintain patency of lines are eligible.
- •Venous thromboembolic events (e.g. deep vein thrombosis or pulmonary embolism) within 6 months of screening.
- •QTC interval of >470 ms on screening.
- •Long QT syndrome or family history of sudden cardiac death in young family members.
- •Subjects who participated in an investigational drug or device study within 28 days prior to study entry.
- •Known active infection with HIV, hepatitis B, or hepatitis C.
- •Females who are pregnant or breast-feeding.
- •Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
- •Unwillingness or inability to comply with the study protocol for any reason.
研究组 & 干预措施
Gemcitabine, bavituximab
Experimental
Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
干预措施: bavituximab (Biological)
Gemcitabine
Active Comparator
Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
时间窗: One year
To compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
次要结局
- Duration of response (DR)(One year)
- Progression-free survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.(One year)
- Determine overall response rate (ORR)(One year)
- Determine the frequency of 25% or greater reduction in CA 19-9 in patients with baseline CA 19-9>=2 time the upper limit of normal (ULN) at screening(One year)
- Safety(One year)
研究者
研究点 (19)
Loading locations...
相似试验
招募中
2 期
A Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)Muscle-Invasive Bladder CarcinomaBladder CancerNCT06571708Columbia University36
终止
2 期
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial CarcinomaUrothelial CarcinomaNCT01353222Dendreon142
已完成
2 期
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyMetastatic Colorectal CancerNCT02743221Institut de Recherches Internationales Servier154
已完成
2 期
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsRectal CancerMetastatic Colorectal CancerColorectal CancerColon CancerNCT00819780Amgen285
已完成
2 期
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT01380769NewLink Genetics Corporation157